- Home
- Companies
- north america
- nasal mucosa
Refine by
Nasal Mucosa Suppliers In North America
5 companies found
based inStockholm, SWEDEN
NoseOption AB is a MedTech company manufacturing and selling nasal breathing devices. With a vision to create a better breathing experience for everyone, NoseOption offers a unique portfolio of nasal devices that filters out odor, allergens, smog, ...
based inMonmouth Junction, NEW JERSEY (USA)
MedChemExpress (MCE) offers a wide range of high-quality research chemicals and biochemicals (novel life-science reagents, reference compounds and natural compounds) for scientific use. We have professionally experienced and friendly staff to meet ...
Fluticasone furoate is a topical, intranasal, enhanced-affinity synthetic trifluorinated corticosteroid with a Kd of 0.3 nM. Fluticasone furoate has potent anti-inflamatory and anti-asthmatic activity, and low systemic exposure. Fluticasone furoate ...
based inOranmore, IRELAND
Neurent Medical is dedicated to developing highly innovative non-surgical interventions that treat chronic inflammatory Sino-Nasal diseases. The privately held, venture backed company is based in Galway Ireland. Neurent Medical was founded by CEO ...
The NEUROMARK System is designed to treat symptoms of chronic rhinitis safely and effectively in the ENT physician’s office with a high degree of patient comfort. The system is engineered to gently apply controlled low-power Radio Frequency ...
based inAnn Arbor, MICHIGAN (USA)
BlueWillow Biologics is a clinical-stage, privately-held biopharmaceutical company focused on developing and commercializing intranasal vaccines using its patented nanoemulsion platform. The platform, originally discovered at the University of ...
BlueWillow’s vaccine technology incorporates nano-scale droplets that are manufactured at an average size of 400–500 nanometers to deliver and adjuvant a broad spectrum of ...
based inMadison, WISCONSIN (USA)
FluGen, Inc. is developing a more effective vaccine in the fight against influenza and respiratory disease. The M2SR Vaccine Platform has the potential to revolutionize the $5 billion annual influenza market, with a clinically-tested vaccine ...